CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...